Expert Discusses Bipolar Androgen Therapy Plus PARP Inhibition for Castration-Resistant Prostate Cancer


CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.

At the 2021 European Society for Medical Oncology Congress, CancerNetwork® spoke with Michael Schweizer, MD, assistant professor in the Division of Medical Oncology at the University of Washington School of Medicine and associate professor of the Clinical Research Division at Fred Hutchinson Cancer Research Center, about his research on the combination regimen of olaparib (Lynparza) plus bipolar androgen therapy (BAT) for patients with castration-resistant prostate cancer (CRPC).

The single-center, phase 2 study (NCT03516812) enrolled 36 patients (median age, 70 years; range, 51-88) with CRPC who received either prior abiraterone acetate (Zytiga) and/or enzalutamide (Xtandi) to receive olaparib at 300 mg orally twice daily plus BAT. Almost half (47%) of patients had a PSA50 response, defined as a 50% or greater decline in their PSA level. At a median follow-up of 22.7 months, the median progression-free survival (PFS) was 12.6 months.

Schweizer said this approach is not ready for the clinic yet, but it holds promise for this group of patients being treated by a medical oncologist.


I don't think this is necessarily going to shift the standard of care right now because it’s a relatively small phase 2 trial. You know, hypothetically, if it turned out that this combination was active, they could prove it in a randomized trial, and it became a standard of care, this would probably still fall predominantly on medical oncology to treat these patients since you're talking about utilizing drugs like PARP inhibitors, which tend to be mostly utilized in the medical oncology field.

In theory, I could see if this really panned out to be a therapy that was effective for an unselected population that perhaps it would start going back towards urologists utilizing it more since it doesn’t require sort of advanced genomic testing. For now, it’s probably not going to necessarily be something that relies heavily on a multidisciplinary approach for utilization since it’s a drug-based treatment.


Schweizer M, Gulati R, Yezefski T, et al. Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2021 European Society for Medical Oncology Congress. September 16-21, 2021. Abstract 592P

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content